Evolent Health, Inc. (EVH): Results of Operations and Financial Condition
Evolent Health, Inc. (EVH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2026q2exhibit991.htm EX-99.1 Document Exhibit 99.1 Evolent Announces Second Quarter 2026 Results WASHINGTON (August 6, 2026) – Evolent Health, Inc. (NYSE: EVH) (“Evolent” or the “Company”), a company that specializes in better health outcomes for people with complex co
How this was made
The 30-second read
Why it matters
Traders can update valuation and positioning based on the raised 2026 revenue range, tightened Adjusted EBITDA range, and the stated 2027 Adjusted EBITDA midpoint target, alongside disclosed Q2 operating metrics and cash position.
Market read
The filing provides fresh, decision-relevant guidance numbers and a 2027 outlook, which can drive immediate repricing versus prior consensus expectations.
What to watch
Adjusted EBITDA margin in the quarter (4.3%) is below the prior-year quarter (8.5%), and the company highlights significant ongoing industry headwinds, which could dominate the market reaction despite higher revenue.
Background
This is an SEC Form 8-K (Item 2.02) with an attached earnings release for Evolent’s second quarter 2026 results, including updated full-year guidance and partnership launch expectations.
Ticker impact
Evolent reported Q2 2026 results and raised 2026 revenue guidance to $2.6 to $2.7 billion, tightening Adjusted EBITDA to $120 to $135 million.
Near-term bias upward on guidance credibility, with volatility risk if investors focus on the still-low Adjusted EBITDA margin and net loss.
The filing discloses specific updated full-year targets and Q2 operating metrics (revenue, net loss, Adjusted EBITDA) plus a 2027 outlook midpoint at or above $150 million, which can drive repricing. However, Adjusted EBITDA margin remains below the prior-year quarter and the company flags ongoing industry attrition headwinds.
Market effects
Reinforces demand for complex specialty care and AI-led operating models among value-based care providers, potentially supporting sentiment for adjacent managed-care enablement platforms.
Primarily US healthcare services/Medicaid exposure, with limited direct regional spillover beyond US payer/provider ecosystems.
Low direct global relevance; impacts are mostly US payer contracting and healthcare services sentiment.
Counterpoint
Investors may discount the guidance raise if they believe Medicaid membership attrition and high medical expense ratios will keep profitability constrained, making the EBITDA targets harder to achieve.
Key entities
- public_companyEvolent Health, Inc.
NYSE-listed healthcare services company reporting Q2 2026 results and updated 2026 guidance, plus 2027 outlook.
- executiveSeth Blackley
Co-Founder and CEO quoted on growth, profitability, cash flow, and an AI-led operational model.
- executiveMario Ramos
CFO quoted on 2027 revenue growth expectations and Adjusted EBITDA outlook drivers.
